Skip To Main Content

Genentech Oncology

THIS WEBSITE IS INTENDED FOR US HEALTHCARE PROFESSIONALS ONLY

Registration

Tiragolumab (anti-TIGIT)

(RG6058, MTIG7192A) 

Gastrointestinal

Phase III

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma (SKYSCRAPER-07)

NCT04543617

VIEW TRIAL

Hematology

Phase II

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05315713

VIEW TRIAL

Phase I

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT04045028

VIEW TRIAL

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05315713

VIEW TRIAL

Lung

Phase III

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

NCT04619797

VIEW TRIAL

A Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Participants with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

NCT04513925

VIEW TRIAL

Phase II

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

NCT04832854

VIEW TRIAL

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (SKYSCRAPER-06)

NCT04619797

VIEW TRIAL

Solid Tumor

Phase I

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab With and Without Chemotherapy in Locally Advanced or Metastatic Tumors

NCT02794571

VIEW TRIAL

This compound and its use are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Targeting TIGIT: A novel immune checkpoint

Tiragolumab, an investigational molecule

TIGIT (T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains) is a novel negative immune checkpoint, expressed on T cells and NK cells.1,2

TIGIT receptor on T cells and NK cells

TIGIT is a coinhibitory receptor that binds to PVR on APCs and tumor cells in various solid and hematologic tumors.1-3 TIGIT dampens the immune response by competing with its costimulatory counterpart, CD226, for binding to PVR.1,2 Once bound to TIGIT, tiragolumab may restore anti-tumor immunity, thereby complementing PD-L1 inhibition, as shown in preclinical models.1 TIGIT was identified at Genentech.2,4

Tiragolumab is an investigational, fully human monoclonal IgG1 antibody designed to prevent PVR-TIGIT interaction.3

Tiragolumab is designed to prevent PVR-TIGIT interaction

Preclinical studies suggest that targeting both TIGIT and PD-L1 may synergistically enhance immune-mediated tumor rejection.1,5,6

Targeting TIGIT on effector T cell

Targeting TIGIT may enhance Teff  function.1

Targeting TIGIT on NK cell

Targeting TIGIT may activate NK cells.5

Targeting TIGIT on regulatory T cell

Targeting TIGIT may counter T reg-mediated immune suppression.6

APC=antigen-presenting cell; IgG1=immunoglobulin G1; NK=natural killer; PD-1=programmed cell death protein 1; PD-L1=programmed cell-death ligand 1; PVR=poliovirus receptor; Teff=effector T cell; Treg=regulatory T cell; TIGIT=T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains.

    • Johnston RJ, Comps-Agrar L, Hackney J, et al. Cancer Cell. 2014;26(6):923-937. PMID: 25465800

      Johnston RJ, Comps-Agrar L, Hackney J, et al. Cancer Cell. 2014;26(6):923-937. PMID: 25465800

    • Yu X, Harden K, Gonzalez LC, et al. Nat Immunol. 2009;10(1):48-57. PMID: 19011627

      Yu X, Harden K, Gonzalez LC, et al. Nat Immunol. 2009;10(1):48-57. PMID: 19011627

    • Sanchez-Correa B, Valhondo I, Hassouneh F, et al. Cancers (Basel). 2019;11(6):877. PMID: 31234588

      Sanchez-Correa B, Valhondo I, Hassouneh F, et al. Cancers (Basel). 2019;11(6):877. PMID: 31234588

    • Abbas AR, Baldwin D, Ma Y, Ouyang W, et al. Genes Immun. 2005;6(4):319-331. PMID: 15789058

      Abbas AR, Baldwin D, Ma Y, Ouyang W, et al. Genes Immun. 2005;6(4):319-331. PMID: 15789058

    • Stanietsky N, Simic H, Arapovic J, et al. Proc Natl Acad Sci USA. 2009;106(42):17858-17863. PMID: 19815499

      Stanietsky N, Simic H, Arapovic J, et al. Proc Natl Acad Sci USA. 2009;106(42):17858-17863. PMID: 19815499

    • Kurtulus S, Sakuishi K, Ngiow SF, et al. J Clin Invest. 2015;125(11):4053-4062. PMID: 26413872

      Kurtulus S, Sakuishi K, Ngiow SF, et al. J Clin Invest. 2015;125(11):4053-4062. PMID: 26413872